Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -157.76% is 12% above its 4-year average of -179.37%, around the middle of its 4-year range (-353.41%–-52.85%).
As of the fiscal period ended Tuesday, June 30, 2026. 23.33% below its 12-month average of -127.92%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2027 (2026-06-30): -157.76%.
RETURN ON EQUITY (ROE)
-157.76%
RETURN ON EQUITY (ROE) AVG TTM
-127.92%
RETURN ON EQUITY (ROE) AVG 3Y
-174.83%
RETURN ON EQUITY (ROE) AVG 5Y
-179.37%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-23.33%
CURRENT VS 3Y AVG
+9.76%
CURRENT VS 5Y AVG
+12.05%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
-275.53%
vs the sector median at left
Valion Bio, Inc.
Market Cap
$9.86M
Return on Equity (ROE)
-157.76%
TTM Avg
-127.92%
3Y Avg
-174.83%
5Y Avg
-179.37%
Market Cap
$9.83M
Return on Equity (ROE)
-189.76%
TTM Avg
-774.75%
3Y Avg
-460.85%
5Y Avg
-442.56%
Market Cap
$9.75M
Return on Equity (ROE)
-211.76%
TTM Avg
-295.58%
3Y Avg
-182.53%
5Y Avg
-207.81%
Market Cap
$9.71M
Return on Equity (ROE)
-57.34%
TTM Avg
-65.47%
3Y Avg
-124.96%
5Y Avg
28.05%
Market Cap
$10.06M
Return on Equity (ROE)
N/A
TTM Avg
18596.99%
3Y Avg
9182.42%
5Y Avg
7349.85%
Market Cap
$10.06M
Return on Equity (ROE)
N/A
TTM Avg
-652.54%
3Y Avg
-364.25%
5Y Avg
-252.47%
Market Cap
$10.13M
Return on Equity (ROE)
-310.94%
TTM Avg
727.99%
3Y Avg
459.17%
5Y Avg
300.20%
Market Cap
$9.50M
Return on Equity (ROE)
-440.15%
TTM Avg
-145.56%
3Y Avg
-96.97%
5Y Avg
-42.16%
Market Cap
$10.21M
Return on Equity (ROE)
-252.37%
TTM Avg
-195.20%
3Y Avg
-116.68%
5Y Avg
-90.09%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Valion Bio, Inc. (VBIO) | $9.86M | -157.76% | -127.92% | -174.83% | -179.37% |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.83M | -189.76% | -774.75% | -460.85% | -442.56% |
| MetaVia Inc. (MTVA)vs › | $9.75M | -211.76% | -295.58% | -182.53% | -207.81% |
| Satellos Bioscience Inc. (MSLE)vs › | $9.71M | -57.34% | -65.47% | -124.96% | 28.05% |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | N/A | 18596.99% | 9182.42% | 7349.85% |
| Senti Biosciences, Inc. (SNTI)vs › | $10.06M | N/A | -652.54% | -364.25% | -252.47% |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.13M | -310.94% | 727.99% | 459.17% | 300.20% |
| Ainos, Inc. (AIMD)vs › | $9.50M | -440.15% | -145.56% | -96.97% | -42.16% |
| Lifeward Ltd. (LFWD)vs › | $10.21M | -252.37% | -195.20% | -116.68% | -90.09% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.45M | -37052.06% | -237.80% | -258.91% | -310.30% |
ROE
-157.8%
ROA
-57.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -157.76% |
| 2026-03-31 | -122.74% |
| 2025-12-31 | -52.85% |
| 2025-09-30 | -134.25% |
| 2025-06-30 | -171.98% |
| 2025-03-31 | -186.96% |
| 2024-12-31 | -223.08% |
| 2024-09-30 | -226.57% |
| 2024-06-30 | -161.02% |
| 2024-03-31 | -353.41% |
| 2023-12-31 | -230.28% |
| 2023-09-30 | -143.19% |
| 2023-06-30 | -287.22% |
| 2023-03-31 | -191.59% |
| 2022-12-31 | -278.13% |
| 2022-09-30 | -200.38% |
| 2022-06-30 | -138.05% |
| 2022-03-31 | -84.54% |
| 2021-12-31 | -64.00% |
| 2021-03-31 | -30.09% |
